Analysis on the in vitro susceptibility test results from two groups of traditional Chinese medicine prescriptions for diabetic foot producing ESBLs Escherichia coli and MRSA

doi:10.3969/j.issn.1673-8640.2015.03.015

Abstract

Abstract: Objective

To understand the inhibitory and treatment effects of Coptis chinensis and Coptis chinensis with Musk prescriptions for diabetic foot producing extended-spectrum beta lactamase (ESBLs) Escherichia coli and methicillin-resistant Staphylococcus aureus (MRSA).

Methods

The patients diagnosed as diabetic foot were enrolled. After culturing, 138 isolates of bacteria were isolated, and 67 isolates of ESBLs Escherichia coli and MRSA were screened. The minimum inhibitory concentrations (MIC) of Coptis chinensis (prescription 1) and Coptis chinensis with Musk (prescription 2) were determined by agar dilution method. The treatment effect of the 2 groups of prescriptions for diabetic foot was observed.

Results

The MIC of prescription 1 for 35 isolates of ESBLs Escherichia coli was ≥128 mg/mL, and the MIC of prescription 2 was 32 mg/mL. The MIC scope of prescription 2 was 32-128 mg/mL. The MIC for 32 isolates of MRSA droped from 32 mg/mL (prescription 1) to 8 mg/mL (prescription 2). Compared with prescription 1, the MIC of prescription 2 decreased significantly, the treatment effect was distinct, and the differences were statistically significant (P<0.05).

Conclusions

Traditional Chinese medicine prescription Coptis chinensis with Musk has inhibitory and treatment effects for diabetic foot producing ESBLs Escherichia coli and MRSA, which is a novel method for clinical treatment.

Key words: Traditional Chinese medicine susceptibility test, Extended-spectrum beta lactamase, Escherichia coli, Methicillin-resistant Staphylococcus aureus, Coptis chinensis, Musk, Diabetic foot

CLC Number:

R446.5

LIANG Xiaoyi, ZHU Haiying, LIU Xiaomei, PAN Min. Analysis on the in vitro susceptibility test results from two groups of traditional Chinese medicine prescriptions for diabetic foot producing ESBLs Escherichia coli and MRSA[J]. Laboratory Medicine, 2015, 30(3): 261-264.

Figures/Tables 3

References 11

[1]	龚岚. 黄莲与冰绷散治疗糖尿病足溃疡的效果观察[J]. 护理学报,2010,17(12):62-63.
[2]	徐灵芝,杨叶虹,叶红英,等. 糖尿病足感染的细菌学特点与预后分析[J]. 浙江临床医学,2008,10(4):451-452.
[3]	董春雷,朱长太.医院分离病原菌分布及药物敏感性分析[J].检验医学,2011,26(10):658-661.
[4]	卢雯玲,刘铜华.中医药防治糖尿病足的研究进展[J]. 中国现代中药,2006,18(10):25-28.
[5]	国家药典委员会. 中华人民共和国药典[M].北京:工业出版社,2005:679.
[6]	中华人民共和国卫生部. 多重耐药菌医院感染预防控制技术指南(试行)[S].卫办医改发[2011]5号,卫生部,2011.
[7]	Clinical and Laboratory Standards Institute. Perform-ance standerds for antimicrobial susceptibility testing; Twenty-second informational supplement[S]. M100-S22, CLSI, 2012.
[8]	中华人民共和国卫生部. 中药新药临床研究指导原则[M].3版. 北京:人民卫生出版社,1997:30.
[9]	倪语星,尚红,刘运德,等. 临床微生物学检验[M]. 5版. 北京:人民卫生出版社,2012:4.
[10]	李碧娟,胡娟娟,刘燕媚,等.中药泡足治疗糖尿病足的效果观察[J].护理学报,2009,16(2): 63-64.
[11]	李继霞,公衍文.多重耐药菌医院感染状况分析[J].检验医学,2013,28(9):784-788.

菌种	药物浓度(mg/mL)
菌种	0.25/3	0.5/3	1/3	2/3	4/3	8/3	16/3	32/3	64/3	128/3
产ESBLs大肠埃希菌	35	35	33	28	19	8	2	-	-	-
MRSA	32	32	24	13	3	-	-	-	-	-

菌种	药物浓度(mg/mL)
菌种	0.25/3	0.5/3	1/3	2/3	4/3	8/3	16/3	32/3	64/3	128/3
产ESBLs大肠埃希菌	35	35	33	28	19	8	2	-	-	-
MRSA	32	32	24	13	3	-	-	-	-	-

组别	例数	治愈	显效	有效	无效
对照组	71	19(26.8)	13(18.3)	17(23.9)	22(31.0)
观察组	67	27(40.3)	22(32.8)	12(17.9)	6(9.0)

组别	例数	治愈	显效	有效	无效
对照组	71	19(26.8)	13(18.3)	17(23.9)	22(31.0)
观察组	67	27(40.3)	22(32.8)	12(17.9)	6(9.0)

[1]	FANG Yongmei, ZHANG Yan, XU Xueying, ZHONG Feng. Correlation of Staphylococcus aureus drug resistance with drug resistance genes and virulence genes [J]. Laboratory Medicine, 2023, 38(4): 357-361.
[2]	ZHANG Cheng, FEI Chunxia, FU Lin, GAO Chenfei, NI Dongying. Correlation analysis of FGF-2,Lp-PLA2 and IGF-1 levels and disease severity in patients with diabetic foot [J]. Laboratory Medicine, 2022, 37(9): 826-830.
[3]	TANG Jin, PAN Yunqi, YANG Yumei, WU Qiong, WANG Jianqiang, LI Yungai, DI Jianzhong. Research progress of methicillin-resistant Staphylococcus aureus screening and decolonization to reduce surgical site infection [J]. Laboratory Medicine, 2022, 37(5): 489-492.
[4]	WEN Qinghui, LI Fengying, LI Yanchang, HUANG Jinyin, WANG Fengping. Drug susceptibility of multidrug-resistant ESBL-producing Escherichia coli to antimicrobial agents restored by different concentrations of EDTA [J]. Laboratory Medicine, 2022, 37(3): 205-208.
[5]	PAN Yunqi, LI Yungai, WANG Jianqiang, WU Qiong, TANG Jin. Analysis of molecular typing,virulence genes and antibiotic susceptibility of uropathogenic Escherichia coli in patients with recurrent urinary tract infection [J]. Laboratory Medicine, 2022, 37(2): 141-145.
[6]	SUN Gang, SUN Hui, DU Yandan, LI Yinyan, LI Yingzhi, DONG Zhanzhu, TONG Lijun, PENG Bo. Study on the drug resistance and molecular epidemiological characteristics of MRSA in Hulunbuir [J]. Laboratory Medicine, 2021, 36(6): 600-603.
[7]	GUO Kunshan, WANG Shanmei, MA Bing, XU Junhong, ZHANG Jiangfeng, JING Nan, YAN Wenjuan, MA Qiong, LI Yi. Application of MALDI-TOF MS in methicillin-resistant Staphylococcus aureus rapid identification [J]. Laboratory Medicine, 2021, 36(2): 209-212.
[8]	LIU Yan, LONG Yin, PAN Weijie, ZHANG Tong, WENG Wenhao, YU Ying. Role of fecal DNA level of Fusobacterium nucleatum and clbA+ Escherichia coli in the diagnosis of colorectal cancer [J]. Laboratory Medicine, 2020, 35(4): 314-317.
[9]	GAO Juyi, WU Chuanan, YANG Weikang, LUO Yuxuan, LIU Shengnan, XU Xiaoping. Role of COP microfluidic chip for the rapid detection of Escherichia coli O157:H7 [J]. Laboratory Medicine, 2020, 35(2): 148-152.
[10]	LIU Cunfen, WANG Yan, YANG Rong, HU Lixiang. Relationship between ESBL genotyping of Escherichia coli and integron in Anning [J]. Laboratory Medicine, 2020, 35(12): 1263-1266.
[11]	LIU Chunlin, XU Bo, CHEN Di, ZHANG Li, WANG Feiying, XU Hongyun, LIU Chang, LÜ Hongling. Distribution and drug resistance analysis of pathogenic bacteria isolated from infectious patients with diabetic foot [J]. Laboratory Medicine, 2019, 34(6): 513-517.
[12]	ZHANG Li, SUN Linchun. Determination and drug resistance gene of methicillin-resistant Staphylococcus aureus isolated from adults in a hospital of Nanjing [J]. Laboratory Medicine, 2019, 34(3): 215-220.
[13]	ZHOU Shan, LIU Jiayun, MA Yueyun, ZHOU Ke, ZHOU Lei, HAO Xiaoke, XU Xiuli. Drug resistance and molecular epidemiology of Staphylococcus aureus with suppurative infection [J]. Laboratory Medicine, 2019, 34(2): 140-143.
[14]	CHEN Wenjing, HE Chunyan, YANG Han, ZHAO Huanqiang, CUI Zelin, TANG Rong, LIU Qingzhong. Drug resistance of methicillin-resistant Staphylococcus aureus to mupirocin,fusidic acid and retapamulin [J]. Laboratory Medicine, 2019, 34(1): 33-37.
[15]	WU Rong, LÜ Yujiang, DAI Junhua, XIANG Fenfen, KONG Qianqian, QIAN Ning, ZHANG Guiliu, YANG Yuling, CHEN Lichun, KANG Xiangdong. Drug resistance of ESBLs-producing Escherichia coli to aminoglycosides and the sequences of drug resistant genes [J]. Laboratory Medicine, 2016, 31(11): 959-964.